Skip to main content

Table 1 Demographics of All Treated Patients (n = 71)

From: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

Demographic

No. of patients

%

Gender

  

 Male

30

42.3

 Female

41

57.7

Median age, years

56

 Range

28-75

Cancer type

  

 Breast

22

31.0

 Lung

14

19.7

 Rectum

9

12.7

 Colon

7

9.9

 Others

5

7.0

 Ovary

4

5.6

 Nasopharynx

3

4.2

 Stomach

5

7.0

 Cervix

1

1.4

 Unknown primary

1

1.4

ECOG performance status

  

 0

17

23.9

 1

54

76.1

 2

0

0

Prior treatment

  

 Chemotherapy

71

100.0

 1 regimen

5

7.0

 2 regimens

6

8.5

 ≥3 regimens

60

84.5

 Surgery

56

78.9

 Radiotherapy

36

50.7

 Hormone therapy

11

15.5

 Targeted therapy

32

45.1

 Others

21

29.6

  1. Abbreviation: No. number, ECOG Eastern Cooperative Oncology Group.